Molecular Partners AG (MOLN) News
Follow Molecular Partners AG (MOLN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Molecular Partners (MOLN) reports H1 2026 results; MP0712 advances dose
Molecular Partners reports H1 2026 financial results and corporate highlights, including DLL3 radiotherapy MP0712 advancing to a higher dose level in its Phase 1/2a study.
EQUITY | Aug 25, 2026, 05:00 AM UTC
L
Molecular Partners And Orano Med Dose First Patients In DLL3-Targeting Radio-DARPin Small Cell Lung Cancer Study
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months,
EQUITY | Jul 02, 2026, 06:24 AM UTC